You are here: Industry Insights > REGN-COV2

News List

EMA initiates rolling review of Regeneron’s COVID-19 mAb europeanpharmaceuticalreview
February 03, 2021
The EMA’s CHMP has begun a rolling review of REGN-COV2, Regeneron’s COVID-19 antibody candidate, after successful pre-clinical trials.
COVID-19 Outpatient Trial Demonstrates REGN-COV2 Antibody Cocktail Reduced Virus Levels americanpharmaceuticalreview
November 09, 2020
Regeneron Pharmaceuticals announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Regeneron to continue patient recruitment for Covid-19 trial pharmaceutical-technology
November 09, 2020
The independent data monitoring committee (DMC) has recommended the continuation of Regeneron’s UK-based RECOVERY trial analysing REGN-COV2 in hospitalised patients with Covid-19.
IDMC recommends modifications to Regeneron COVID-19 antibody trial europeanpharmaceuticalreview
November 06, 2020
The clinical trial testing the REGN-COV2 antibody cocktail should be altered, according to the Independent Data Monitoring Committee (IDMC).
Can an antibody 'cocktail' prevent COVID-19 infection? worldpharmanews
October 15, 2020
In a new clinical trial, UC Davis Health will test the effectiveness and safety of REGN-COV2, the monoclonal antibody cocktail, in preventing COVID-19 in adults living with infected patients.
Regeneron's REGN-COV2 antibody cocktail reduced viral levels and improved symptoms in non-hospitalized COVID-19 patients worldpharmanews
October 15, 2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it reduced viral load and the time to alleviate symptoms in ...
Phase III trial to study REGN-COV2, potential COVID-19 antibody treatment europeanpharmaceuticalreview
September 17, 2020
REGN-COV2 will be evaluated alongside standard-of-care in a Phase III study as part of the COVID-19 RECOVERY trial.
Regeneron to create 400 jobs to support manufacturing in Ireland pharmaceutical-technology
August 31, 2020
Regeneron Pharmaceuticals has plans to add more than 400 new jobs to its Industrial Operations and Product Supply (IOPS) campus in Limerick, Ireland.
Roche teams up with Regeneron on Covid-19 therapy pharmaceutical-technology
August 21, 2020
Roche has partnered with Regeneron Pharmaceuticals to develop, manufacture and distribute the latter’s antiviral antibody combination, REGN-COV2, as a potential treatment of Covid-19.
Roche, Regeneron Partner to Increase Global Supply of REGN-COV2 contractpharma
August 20, 2020
To develop, manufacture and distribute REGN-COV2, Regeneron’s investigational antiviral antibody combination to treat COVID-19.

Previous page 1 2 Next page